pISSN 1226-6051
eISSN 2508-786X

Table. 1.

Table. 1.

Baseline characteristics of trials and participants

Study N Age (years) N (%), Intervention Intensive therapy Placebo/less intensive therapy Follow-up (years)



Women Diabetes Active agent N LDL-C Baseline LDL-C Active agent N LDL-C
Tamio 201823) 163 63.6 20(38.7) 32(60.4) Alirocumab 53 47.4 149.2 Placebo 56 143.6 1.8
Koh 201724) 199 61.2 14(14.4) 32(33.0) Alirocumab 97 42.7 97.0 Placebo 102 102.9 0.5
Liu 201725) 219 84.0 54(47.4) 46(40.4) Statin+ezetimibe 108 46.4 85.1 Statin 111 54.1 1.0
Sabatine 20175) 27,564 62.5 6769(25.0) 10081(37.0) Evolocumab 13,784 30.0 92.0 Placebo 13,780 92.0 2.2
Tamio 201626) 216 60.3 60(41.7) 105(72.9) Alirocumab 144 53.4 143.1 Placebo 72 135.6 1.8
Cannon 20154) 18,144 63.6 4416(24.0) 4933(27.0) Statin+ezetimibe 9067 54.0 93.8 Statin 9077 70.0 6.0
Sabatine 201527) 4465 58.0 2210(49.5) 599(13.4) Evolocumab 2976 48.0 120.5 Statin 1489 121.0 0.9
Korean J Clin Pharm 2023;33:270-7 https://doi.org/10.24304/kjcp.2023.33.4.270
© 2023 Korean J Clin Pharm